| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Climate Change | 16 | 2025 | 27 | 6.340 |
Why?
|
| Sex Workers | 28 | 2020 | 116 | 5.040 |
Why?
|
| HIV Infections | 92 | 2024 | 5097 | 4.740 |
Why?
|
| Pregnancy Complications, Infectious | 21 | 2021 | 529 | 4.090 |
Why?
|
| Humans | 180 | 2025 | 14537 | 3.600 |
Why?
|
| Female | 144 | 2024 | 9103 | 3.190 |
Why?
|
| Sexual Behavior | 28 | 2021 | 320 | 2.870 |
Why?
|
| Pregnancy | 63 | 2024 | 1862 | 2.860 |
Why?
|
| Health Services Accessibility | 16 | 2019 | 280 | 2.810 |
Why?
|
| Maternal Health | 9 | 2024 | 20 | 2.650 |
Why?
|
| Adult | 103 | 2024 | 5913 | 2.610 |
Why?
|
| Alcohol Drinking | 11 | 2017 | 55 | 2.470 |
Why?
|
| Research | 6 | 2021 | 65 | 2.420 |
Why?
|
| Patient Acceptance of Health Care | 15 | 2019 | 256 | 2.390 |
Why?
|
| Infectious Disease Transmission, Vertical | 15 | 2021 | 472 | 2.360 |
Why?
|
| South Africa | 91 | 2024 | 7596 | 2.340 |
Why?
|
| Anti-HIV Agents | 28 | 2023 | 1324 | 2.110 |
Why?
|
| Developing Countries | 8 | 2018 | 400 | 2.100 |
Why?
|
| Hot Temperature | 8 | 2025 | 28 | 2.050 |
Why?
|
| Premature Birth | 5 | 2024 | 80 | 2.000 |
Why?
|
| Sexually Transmitted Diseases | 15 | 2020 | 103 | 1.900 |
Why?
|
| Attitude of Health Personnel | 7 | 2019 | 106 | 1.850 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 7 | 2017 | 9 | 1.840 |
Why?
|
| Anti-Retroviral Agents | 12 | 2023 | 551 | 1.820 |
Why?
|
| Prenatal Care | 10 | 2020 | 147 | 1.760 |
Why?
|
| Sex Work | 14 | 2020 | 39 | 1.760 |
Why?
|
| Unsafe Sex | 15 | 2019 | 46 | 1.740 |
Why?
|
| Global Health | 5 | 2024 | 193 | 1.720 |
Why?
|
| Kenya | 34 | 2024 | 183 | 1.650 |
Why?
|
| Papillomavirus Infections | 8 | 2020 | 74 | 1.580 |
Why?
|
| Young Adult | 54 | 2021 | 2498 | 1.560 |
Why?
|
| Healthcare Disparities | 4 | 2018 | 43 | 1.530 |
Why?
|
| Adolescent | 44 | 2021 | 2985 | 1.420 |
Why?
|
| Health Personnel | 6 | 2020 | 231 | 1.410 |
Why?
|
| Violence | 6 | 2019 | 68 | 1.390 |
Why?
|
| Maternal Health Services | 8 | 2018 | 52 | 1.340 |
Why?
|
| Contraception Behavior | 6 | 2020 | 54 | 1.330 |
Why?
|
| Reproductive Health Services | 8 | 2018 | 66 | 1.320 |
Why?
|
| Stillbirth | 3 | 2024 | 83 | 1.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 71 | 1.270 |
Why?
|
| Male | 58 | 2024 | 6754 | 1.270 |
Why?
|
| Maternal Mortality | 6 | 2024 | 58 | 1.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 1.250 |
Why?
|
| Infant, Newborn | 21 | 2024 | 1479 | 1.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 13 | 2014 | 262 | 1.200 |
Why?
|
| Risk Factors | 29 | 2021 | 1475 | 1.200 |
Why?
|
| Long-Acting Reversible Contraception | 5 | 2019 | 11 | 1.180 |
Why?
|
| Socioeconomic Factors | 12 | 2025 | 411 | 1.170 |
Why?
|
| Contraception | 7 | 2017 | 90 | 1.170 |
Why?
|
| Listeriosis | 2 | 2018 | 8 | 1.160 |
Why?
|
| Cross-Sectional Studies | 30 | 2022 | 1422 | 1.160 |
Why?
|
| Health Policy | 7 | 2024 | 140 | 1.150 |
Why?
|
| Urban Population | 5 | 2017 | 257 | 1.120 |
Why?
|
| Greenhouse Gases | 2 | 2024 | 4 | 1.110 |
Why?
|
| Internationality | 3 | 2016 | 36 | 1.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 9 | 2020 | 472 | 1.070 |
Why?
|
| Optimism | 1 | 2024 | 1 | 0.950 |
Why?
|
| Risk-Taking | 11 | 2020 | 121 | 0.950 |
Why?
|
| Women's Health | 6 | 2019 | 41 | 0.940 |
Why?
|
| Middle Aged | 31 | 2020 | 3601 | 0.930 |
Why?
|
| Infant Health | 7 | 2024 | 16 | 0.890 |
Why?
|
| Extreme Heat | 1 | 2023 | 3 | 0.880 |
Why?
|
| Mothers | 6 | 2024 | 195 | 0.880 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 56 | 0.870 |
Why?
|
| Health Priorities | 2 | 2018 | 62 | 0.850 |
Why?
|
| Public Health | 4 | 2024 | 124 | 0.850 |
Why?
|
| Qualitative Research | 12 | 2023 | 321 | 0.840 |
Why?
|
| Adolescent Health | 2 | 2019 | 15 | 0.800 |
Why?
|
| HIV-1 | 10 | 2021 | 1260 | 0.790 |
Why?
|
| Mass Screening | 3 | 2020 | 245 | 0.790 |
Why?
|
| Prevalence | 23 | 2022 | 1192 | 0.780 |
Why?
|
| Pandemics | 3 | 2021 | 296 | 0.770 |
Why?
|
| Transients and Migrants | 5 | 2017 | 39 | 0.770 |
Why?
|
| HIV | 5 | 2019 | 380 | 0.770 |
Why?
|
| Disease Outbreaks | 2 | 2020 | 111 | 0.750 |
Why?
|
| Postpartum Period | 7 | 2024 | 85 | 0.740 |
Why?
|
| Infant, Low Birth Weight | 2 | 2020 | 35 | 0.740 |
Why?
|
| Public Sector | 3 | 2018 | 82 | 0.740 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 151 | 0.730 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2019 | 115 | 0.720 |
Why?
|
| Pregnancy, Unplanned | 7 | 2020 | 19 | 0.720 |
Why?
|
| Primary Health Care | 4 | 2019 | 240 | 0.720 |
Why?
|
| Research Design | 3 | 2024 | 124 | 0.710 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 11 | 0.700 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 34 | 0.700 |
Why?
|
| Maternal Death | 2 | 2017 | 25 | 0.690 |
Why?
|
| Colposcopy | 2 | 2019 | 17 | 0.680 |
Why?
|
| Occupational Exposure | 1 | 2020 | 35 | 0.670 |
Why?
|
| Health Services Needs and Demand | 3 | 2017 | 57 | 0.670 |
Why?
|
| Counseling | 5 | 2014 | 143 | 0.670 |
Why?
|
| Political Activism | 1 | 2019 | 3 | 0.670 |
Why?
|
| Sentinel Surveillance | 1 | 2020 | 115 | 0.670 |
Why?
|
| Safe Sex | 7 | 2020 | 68 | 0.670 |
Why?
|
| Coinfection | 2 | 2024 | 276 | 0.670 |
Why?
|
| Infant | 19 | 2024 | 2244 | 0.670 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 71 | 0.660 |
Why?
|
| Global Warming | 1 | 2019 | 1 | 0.660 |
Why?
|
| Sexual Partners | 10 | 2019 | 215 | 0.660 |
Why?
|
| Surveys and Questionnaires | 14 | 2018 | 563 | 0.650 |
Why?
|
| Health Care Sector | 1 | 2019 | 8 | 0.650 |
Why?
|
| Tenofovir | 5 | 2021 | 171 | 0.640 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2024 | 19 | 0.640 |
Why?
|
| Cities | 6 | 2024 | 37 | 0.630 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 22 | 0.630 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2019 | 656 | 0.630 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2019 | 36 | 0.620 |
Why?
|
| Device Removal | 5 | 2017 | 14 | 0.620 |
Why?
|
| Water Microbiology | 1 | 2018 | 3 | 0.610 |
Why?
|
| Food Microbiology | 1 | 2018 | 4 | 0.610 |
Why?
|
| United Nations | 1 | 2018 | 12 | 0.610 |
Why?
|
| Government Employees | 1 | 2018 | 3 | 0.600 |
Why?
|
| Alcoholism | 2 | 2017 | 17 | 0.600 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.590 |
Why?
|
| Private Sector | 1 | 2018 | 45 | 0.570 |
Why?
|
| Endophthalmitis | 1 | 2017 | 1 | 0.560 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 1 | 0.560 |
Why?
|
| Publications | 1 | 2017 | 2 | 0.560 |
Why?
|
| Cost-Benefit Analysis | 2 | 2025 | 253 | 0.560 |
Why?
|
| Listeria monocytogenes | 1 | 2017 | 6 | 0.550 |
Why?
|
| Drinking Behavior | 1 | 2016 | 2 | 0.550 |
Why?
|
| Papillomaviridae | 4 | 2020 | 34 | 0.540 |
Why?
|
| Authorship | 1 | 2016 | 2 | 0.540 |
Why?
|
| Cohort Studies | 13 | 2022 | 967 | 0.530 |
Why?
|
| International Cooperation | 1 | 2016 | 50 | 0.530 |
Why?
|
| Soccer | 2 | 2014 | 10 | 0.530 |
Why?
|
| Transgender Persons | 4 | 2022 | 24 | 0.520 |
Why?
|
| Physicians | 1 | 2016 | 31 | 0.510 |
Why?
|
| Hepatitis B | 1 | 2017 | 125 | 0.510 |
Why?
|
| Family Planning Services | 5 | 2020 | 46 | 0.510 |
Why?
|
| Urban Health | 2 | 2015 | 78 | 0.510 |
Why?
|
| Interpersonal Relations | 2 | 2013 | 43 | 0.500 |
Why?
|
| Health Behavior | 3 | 2016 | 79 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 127 | 0.490 |
Why?
|
| Stavudine | 4 | 2019 | 78 | 0.480 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 293 | 0.470 |
Why?
|
| Pregnant Women | 4 | 2023 | 89 | 0.460 |
Why?
|
| Nevirapine | 6 | 2013 | 146 | 0.460 |
Why?
|
| Temperature | 6 | 2024 | 56 | 0.460 |
Why?
|
| Focus Groups | 8 | 2016 | 196 | 0.450 |
Why?
|
| Pre-Exposure Prophylaxis | 4 | 2022 | 196 | 0.440 |
Why?
|
| Needs Assessment | 4 | 2017 | 29 | 0.440 |
Why?
|
| Human Rights Abuses | 1 | 2013 | 2 | 0.440 |
Why?
|
| Mental Health | 3 | 2020 | 91 | 0.440 |
Why?
|
| Resilience, Psychological | 1 | 2013 | 11 | 0.430 |
Why?
|
| Disease Transmission, Infectious | 1 | 2013 | 39 | 0.420 |
Why?
|
| Anemia | 4 | 2017 | 41 | 0.420 |
Why?
|
| Social Stigma | 1 | 2013 | 80 | 0.400 |
Why?
|
| Truth Disclosure | 2 | 2012 | 18 | 0.390 |
Why?
|
| Condoms | 8 | 2013 | 88 | 0.390 |
Why?
|
| Health Promotion | 4 | 2020 | 109 | 0.390 |
Why?
|
| Hygiene | 2 | 2011 | 23 | 0.390 |
Why?
|
| World Health Organization | 3 | 2024 | 137 | 0.390 |
Why?
|
| Hospital Planning | 1 | 2011 | 1 | 0.380 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 48 | 0.380 |
Why?
|
| Africa | 6 | 2025 | 376 | 0.380 |
Why?
|
| Incidence | 7 | 2021 | 685 | 0.380 |
Why?
|
| Logistic Models | 6 | 2018 | 254 | 0.370 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2021 | 85 | 0.370 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2017 | 187 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 8 | 2017 | 125 | 0.370 |
Why?
|
| Self Medication | 1 | 2010 | 3 | 0.370 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 16 | 0.360 |
Why?
|
| Time Factors | 7 | 2019 | 507 | 0.360 |
Why?
|
| Health Status | 5 | 2018 | 111 | 0.340 |
Why?
|
| Betacoronavirus | 2 | 2020 | 52 | 0.340 |
Why?
|
| Gonorrhea | 3 | 2012 | 20 | 0.340 |
Why?
|
| Interviews as Topic | 7 | 2018 | 203 | 0.340 |
Why?
|
| Communicable Diseases | 2 | 2022 | 62 | 0.340 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 9 | 0.340 |
Why?
|
| Anal Canal | 3 | 2019 | 7 | 0.340 |
Why?
|
| Vulnerable Populations | 4 | 2021 | 30 | 0.340 |
Why?
|
| Intrauterine Devices | 3 | 2019 | 9 | 0.330 |
Why?
|
| Directly Observed Therapy | 4 | 2010 | 6 | 0.330 |
Why?
|
| Text Messaging | 2 | 2020 | 25 | 0.320 |
Why?
|
| Telemedicine | 2 | 2020 | 25 | 0.320 |
Why?
|
| Drug Interactions | 2 | 2021 | 31 | 0.320 |
Why?
|
| Perception | 3 | 2019 | 42 | 0.310 |
Why?
|
| Africa South of the Sahara | 9 | 2024 | 353 | 0.310 |
Why?
|
| Condylomata Acuminata | 2 | 2019 | 4 | 0.310 |
Why?
|
| Women, Working | 1 | 2008 | 3 | 0.300 |
Why?
|
| Prospective Studies | 9 | 2024 | 1160 | 0.300 |
Why?
|
| Trichomonas Infections | 1 | 2007 | 5 | 0.300 |
Why?
|
| Vaginal Douching | 4 | 2011 | 8 | 0.300 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2007 | 1 | 0.290 |
Why?
|
| Syphilis | 1 | 2007 | 14 | 0.290 |
Why?
|
| Pregnancy Outcome | 2 | 2019 | 117 | 0.290 |
Why?
|
| Health Services | 3 | 2018 | 51 | 0.290 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 80 | 0.290 |
Why?
|
| Viral Load | 6 | 2023 | 819 | 0.280 |
Why?
|
| Vagina | 5 | 2011 | 91 | 0.280 |
Why?
|
| Breast Feeding | 4 | 2024 | 120 | 0.270 |
Why?
|
| Papanicolaou Test | 3 | 2019 | 29 | 0.270 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 112 | 0.270 |
Why?
|
| Quality of Health Care | 2 | 2018 | 62 | 0.270 |
Why?
|
| Residence Characteristics | 3 | 2017 | 57 | 0.270 |
Why?
|
| Family Characteristics | 2 | 2017 | 135 | 0.260 |
Why?
|
| Reproductive Health | 4 | 2020 | 51 | 0.260 |
Why?
|
| Piperazines | 3 | 2021 | 82 | 0.260 |
Why?
|
| Oxazines | 3 | 2021 | 81 | 0.260 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 91 | 0.260 |
Why?
|
| Pyridones | 3 | 2021 | 100 | 0.250 |
Why?
|
| Quality Improvement | 4 | 2017 | 34 | 0.250 |
Why?
|
| Insurance, Health | 2 | 2018 | 16 | 0.250 |
Why?
|
| Vaginosis, Bacterial | 3 | 2011 | 19 | 0.250 |
Why?
|
| Aged | 5 | 2021 | 1740 | 0.240 |
Why?
|
| Bias | 1 | 2024 | 15 | 0.240 |
Why?
|
| Zoonoses | 2 | 2021 | 4 | 0.240 |
Why?
|
| Policy Making | 3 | 2022 | 32 | 0.230 |
Why?
|
| Sex Offenses | 4 | 2017 | 29 | 0.230 |
Why?
|
| Mozambique | 7 | 2018 | 55 | 0.230 |
Why?
|
| Machine Learning | 1 | 2024 | 22 | 0.230 |
Why?
|
| Vaginal Smears | 2 | 2019 | 34 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2019 | 133 | 0.230 |
Why?
|
| Greenhouse Effect | 1 | 2024 | 2 | 0.230 |
Why?
|
| Climate | 1 | 2024 | 5 | 0.230 |
Why?
|
| Hazardous Substances | 1 | 2024 | 3 | 0.230 |
Why?
|
| Kangaroo-Mother Care Method | 1 | 2024 | 4 | 0.230 |
Why?
|
| Zimbabwe | 3 | 2014 | 120 | 0.220 |
Why?
|
| Patient Compliance | 5 | 2018 | 120 | 0.220 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2004 | 59 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2020 | 889 | 0.220 |
Why?
|
| Social Class | 5 | 2016 | 73 | 0.220 |
Why?
|
| Child Health | 1 | 2024 | 77 | 0.220 |
Why?
|
| Population Health | 1 | 2022 | 10 | 0.210 |
Why?
|
| Cell Phone | 2 | 2020 | 34 | 0.210 |
Why?
|
| Sudden Infant Death | 1 | 2022 | 2 | 0.210 |
Why?
|
| Biodiversity | 1 | 2022 | 11 | 0.200 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 21 | 0.200 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.200 |
Why?
|
| Adenine | 2 | 2020 | 91 | 0.200 |
Why?
|
| Health Surveys | 3 | 2011 | 59 | 0.200 |
Why?
|
| Sex Education | 2 | 2013 | 17 | 0.200 |
Why?
|
| Health Care Costs | 3 | 2019 | 115 | 0.190 |
Why?
|
| Disasters | 1 | 2021 | 1 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2021 | 7 | 0.190 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 12 | 0.190 |
Why?
|
| One Health | 1 | 2021 | 1 | 0.190 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2021 | 6 | 0.190 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.180 |
Why?
|
| Ambulatory Care | 2 | 2018 | 54 | 0.180 |
Why?
|
| Uganda | 3 | 2019 | 197 | 0.180 |
Why?
|
| Maternal Welfare | 2 | 2014 | 9 | 0.180 |
Why?
|
| India | 5 | 2018 | 62 | 0.180 |
Why?
|
| Medically Uninsured | 2 | 2018 | 9 | 0.170 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 16 | 0.170 |
Why?
|
| Stereotyping | 2 | 2010 | 5 | 0.170 |
Why?
|
| Attitude to Health | 2 | 2011 | 56 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 31 | 0.170 |
Why?
|
| Zidovudine | 2 | 2013 | 59 | 0.170 |
Why?
|
| Anus Diseases | 1 | 2019 | 3 | 0.170 |
Why?
|
| Child, Preschool | 6 | 2018 | 1748 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2018 | 799 | 0.170 |
Why?
|
| Anti-Infective Agents | 2 | 2012 | 57 | 0.170 |
Why?
|
| Parturition | 3 | 2018 | 31 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.160 |
Why?
|
| Public Policy | 1 | 2019 | 24 | 0.160 |
Why?
|
| Demography | 2 | 2017 | 105 | 0.160 |
Why?
|
| Aggression | 1 | 2019 | 13 | 0.160 |
Why?
|
| Fathers | 2 | 2018 | 9 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2019 | 9 | 0.160 |
Why?
|
| Contraceptive Devices, Female | 3 | 2008 | 30 | 0.160 |
Why?
|
| Cesarean Section | 2 | 2017 | 87 | 0.160 |
Why?
|
| Fertilization | 1 | 2019 | 22 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 38 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 171 | 0.160 |
Why?
|
| Weather | 1 | 2018 | 7 | 0.160 |
Why?
|
| Kidney | 1 | 2019 | 46 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 39 | 0.150 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 6 | 0.150 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 3 | 0.150 |
Why?
|
| Lipids | 1 | 2018 | 81 | 0.150 |
Why?
|
| Foodborne Diseases | 1 | 2018 | 6 | 0.150 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 6 | 0.150 |
Why?
|
| Community Participation | 2 | 2018 | 42 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 8 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 4 | 0.150 |
Why?
|
| Father-Child Relations | 1 | 2018 | 1 | 0.150 |
Why?
|
| Paternal Behavior | 1 | 2018 | 1 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2018 | 79 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2018 | 2 | 0.150 |
Why?
|
| Social Security | 1 | 2018 | 3 | 0.150 |
Why?
|
| Hospitals, Public | 1 | 2018 | 45 | 0.150 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 62 | 0.150 |
Why?
|
| Product Line Management | 1 | 2017 | 1 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 109 | 0.150 |
Why?
|
| Heterosexuality | 1 | 2018 | 30 | 0.150 |
Why?
|
| Group Homes | 1 | 2017 | 1 | 0.150 |
Why?
|
| Health Facility Administration | 1 | 2017 | 1 | 0.150 |
Why?
|
| Depression | 2 | 2017 | 121 | 0.150 |
Why?
|
| Reproductive Behavior | 1 | 2017 | 3 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 16 | 0.150 |
Why?
|
| Alcoholic Intoxication | 1 | 2017 | 3 | 0.140 |
Why?
|
| Transaminases | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antigens | 1 | 2017 | 11 | 0.140 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2017 | 3 | 0.140 |
Why?
|
| Neutropenia | 1 | 2017 | 9 | 0.140 |
Why?
|
| Genitalia, Male | 1 | 2017 | 9 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 20 | 0.140 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 7 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 43 | 0.140 |
Why?
|
| Sexual Health | 1 | 2017 | 14 | 0.140 |
Why?
|
| Community Networks | 1 | 2017 | 13 | 0.140 |
Why?
|
| Refugees | 1 | 2017 | 10 | 0.140 |
Why?
|
| Creatinine | 1 | 2017 | 53 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2017 | 40 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.140 |
Why?
|
| Cost Savings | 1 | 2016 | 7 | 0.140 |
Why?
|
| Drug Costs | 1 | 2016 | 18 | 0.140 |
Why?
|
| Health Education | 3 | 2017 | 35 | 0.140 |
Why?
|
| Alcohol Abstinence | 1 | 2016 | 2 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 17 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2016 | 16 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2016 | 35 | 0.130 |
Why?
|
| Child Development | 1 | 2017 | 93 | 0.130 |
Why?
|
| Crime Victims | 2 | 2017 | 5 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 25 | 0.130 |
Why?
|
| Family | 1 | 2016 | 35 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 239 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 25 | 0.130 |
Why?
|
| Financing, Personal | 2 | 2017 | 12 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 14 | 0.130 |
Why?
|
| Gender Identity | 1 | 2015 | 23 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 237 | 0.120 |
Why?
|
| AIDS Vaccines | 1 | 2017 | 152 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2021 | 167 | 0.120 |
Why?
|
| Vaccination | 1 | 2017 | 365 | 0.120 |
Why?
|
| Financing, Organized | 1 | 2014 | 3 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2014 | 6 | 0.120 |
Why?
|
| Heat Stress Disorders | 2 | 2025 | 2 | 0.120 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2014 | 5 | 0.120 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 265 | 0.120 |
Why?
|
| RNA, Viral | 2 | 2019 | 303 | 0.120 |
Why?
|
| Financing, Government | 1 | 2014 | 11 | 0.120 |
Why?
|
| Spouse Abuse | 1 | 2014 | 12 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2011 | 30 | 0.110 |
Why?
|
| Culture | 2 | 2011 | 23 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 435 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2013 | 3 | 0.110 |
Why?
|
| Medicine, African Traditional | 2 | 2011 | 25 | 0.110 |
Why?
|
| Motor Vehicles | 1 | 2013 | 5 | 0.110 |
Why?
|
| Occupations | 1 | 2013 | 13 | 0.110 |
Why?
|
| Spouses | 1 | 2013 | 6 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.110 |
Why?
|
| Morbidity | 2 | 2018 | 37 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2010 | 17 | 0.110 |
Why?
|
| Refusal to Treat | 1 | 2013 | 3 | 0.110 |
Why?
|
| Postpartum Hemorrhage | 1 | 2014 | 75 | 0.110 |
Why?
|
| Harm Reduction | 1 | 2013 | 7 | 0.110 |
Why?
|
| Public Health Administration | 1 | 2013 | 14 | 0.110 |
Why?
|
| Government Programs | 1 | 2013 | 30 | 0.100 |
Why?
|
| Occupational Health | 1 | 2013 | 24 | 0.100 |
Why?
|
| Cause of Death | 2 | 2014 | 221 | 0.100 |
Why?
|
| Motivation | 3 | 2017 | 59 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2012 | 27 | 0.100 |
Why?
|
| Maternal Behavior | 1 | 2011 | 3 | 0.100 |
Why?
|
| Lamivudine | 2 | 2013 | 89 | 0.100 |
Why?
|
| Economics, Hospital | 1 | 2011 | 1 | 0.100 |
Why?
|
| Efficiency | 1 | 2011 | 3 | 0.100 |
Why?
|
| Ceremonial Behavior | 1 | 2011 | 2 | 0.100 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2011 | 8 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 22 | 0.090 |
Why?
|
| Public Opinion | 1 | 2011 | 6 | 0.090 |
Why?
|
| Financial Support | 1 | 2011 | 10 | 0.090 |
Why?
|
| Teaching | 1 | 2011 | 8 | 0.090 |
Why?
|
| Emtricitabine | 2 | 2021 | 78 | 0.090 |
Why?
|
| Genitalia, Female | 1 | 2010 | 17 | 0.090 |
Why?
|
| Cluster Analysis | 2 | 2020 | 65 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 78 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 11 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 39 | 0.080 |
Why?
|
| Social Environment | 1 | 2009 | 11 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 284 | 0.080 |
Why?
|
| Sexuality | 1 | 2009 | 11 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2009 | 40 | 0.080 |
Why?
|
| Medical Audit | 2 | 2009 | 26 | 0.080 |
Why?
|
| Africa, Southern | 1 | 2008 | 91 | 0.080 |
Why?
|
| Burkina Faso | 2 | 2022 | 29 | 0.080 |
Why?
|
| United States | 2 | 2024 | 132 | 0.080 |
Why?
|
| Students | 1 | 2008 | 50 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2019 | 272 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 370 | 0.080 |
Why?
|
| Anecdotes as Topic | 1 | 2008 | 1 | 0.070 |
Why?
|
| Child Care | 1 | 2008 | 5 | 0.070 |
Why?
|
| Schools | 1 | 2008 | 73 | 0.070 |
Why?
|
| Homosexuality, Male | 2 | 2019 | 52 | 0.070 |
Why?
|
| Animals | 2 | 2021 | 1081 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 19 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 195 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 101 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2007 | 60 | 0.070 |
Why?
|
| Contraception, Barrier | 1 | 2007 | 5 | 0.070 |
Why?
|
| Alkynes | 2 | 2020 | 117 | 0.070 |
Why?
|
| Cyclopropanes | 2 | 2020 | 123 | 0.070 |
Why?
|
| Benzoxazines | 2 | 2020 | 123 | 0.070 |
Why?
|
| Poverty | 2 | 2018 | 152 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 279 | 0.060 |
Why?
|
| Europe | 1 | 2025 | 56 | 0.060 |
Why?
|
| Satellite Imagery | 1 | 2024 | 1 | 0.060 |
Why?
|
| Sex Factors | 2 | 2017 | 227 | 0.060 |
Why?
|
| Infant Welfare | 1 | 2004 | 2 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2017 | 480 | 0.060 |
Why?
|
| Community Health Services | 2 | 2018 | 58 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 17 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 55 | 0.060 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 38 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 149 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 385 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2022 | 2 | 0.050 |
Why?
|
| Income | 2 | 2013 | 85 | 0.050 |
Why?
|
| Malaria | 1 | 2024 | 213 | 0.050 |
Why?
|
| Chlamydia Infections | 2 | 2012 | 17 | 0.050 |
Why?
|
| Educational Status | 2 | 2013 | 68 | 0.050 |
Why?
|
| North America | 1 | 2021 | 11 | 0.050 |
Why?
|
| Middle East | 1 | 2021 | 8 | 0.050 |
Why?
|
| Acclimatization | 1 | 2021 | 2 | 0.050 |
Why?
|
| Perinatal Care | 2 | 2015 | 21 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2013 | 26 | 0.050 |
Why?
|
| Data Collection | 2 | 2013 | 86 | 0.050 |
Why?
|
| Administration, Intravaginal | 2 | 2011 | 50 | 0.050 |
Why?
|
| Alanine | 1 | 2020 | 31 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 111 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 165 | 0.040 |
Why?
|
| Genitalia | 1 | 2019 | 8 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Medication Adherence | 2 | 2010 | 151 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 107 | 0.040 |
Why?
|
| Septal Occluder Device | 1 | 2018 | 2 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2018 | 11 | 0.040 |
Why?
|
| Intention | 1 | 2018 | 23 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2018 | 12 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 16 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2018 | 107 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Amenorrhea | 1 | 2017 | 9 | 0.040 |
Why?
|
| Menstruation Disturbances | 1 | 2017 | 7 | 0.040 |
Why?
|
| Baltimore | 1 | 2017 | 5 | 0.040 |
Why?
|
| Men's Health | 1 | 2017 | 3 | 0.040 |
Why?
|
| Ethanol | 1 | 2017 | 3 | 0.040 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 4 | 0.040 |
Why?
|
| Altruism | 1 | 2017 | 7 | 0.040 |
Why?
|
| Informed Consent | 1 | 2017 | 8 | 0.040 |
Why?
|
| China | 1 | 2017 | 21 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 217 | 0.040 |
Why?
|
| Africa, Eastern | 1 | 2017 | 17 | 0.040 |
Why?
|
| Nigeria | 1 | 2017 | 49 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2018 | 97 | 0.040 |
Why?
|
| Safety | 1 | 2017 | 34 | 0.040 |
Why?
|
| Patient Selection | 1 | 2017 | 40 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 40 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2017 | 60 | 0.030 |
Why?
|
| Health Facility Administrators | 1 | 2016 | 1 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 5 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 23 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 76 | 0.030 |
Why?
|
| Pregnancy, Unwanted | 1 | 2016 | 9 | 0.030 |
Why?
|
| Diet | 1 | 2017 | 109 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 468 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 442 | 0.030 |
Why?
|
| Human Trafficking | 1 | 2014 | 2 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 58 | 0.030 |
Why?
|
| Social Support | 1 | 2014 | 77 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 106 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 60 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2013 | 52 | 0.030 |
Why?
|
| Binge Drinking | 1 | 2013 | 1 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 38 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.030 |
Why?
|
| Voluntary Programs | 1 | 2013 | 5 | 0.030 |
Why?
|
| Employment | 1 | 2013 | 27 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 34 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 2013 | 29 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 2012 | 23 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 5 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2011 | 18 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.020 |
Why?
|
| Maternal Age | 1 | 2011 | 22 | 0.020 |
Why?
|
| Indonesia | 1 | 2011 | 7 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2011 | 15 | 0.020 |
Why?
|
| Thailand | 1 | 2011 | 26 | 0.020 |
Why?
|
| Coercion | 1 | 2011 | 1 | 0.020 |
Why?
|
| Negotiating | 1 | 2011 | 8 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 89 | 0.020 |
Why?
|
| Rwanda | 1 | 2011 | 30 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 107 | 0.020 |
Why?
|
| Fees and Charges | 1 | 2011 | 6 | 0.020 |
Why?
|
| Transportation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Reproductive Medicine | 1 | 2010 | 4 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2011 | 20 | 0.020 |
Why?
|
| Self Administration | 1 | 2010 | 5 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 31 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2010 | 22 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 89 | 0.020 |
Why?
|
| Rural Health | 1 | 2010 | 118 | 0.020 |
Why?
|
| Social Control, Informal | 1 | 2009 | 5 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 188 | 0.020 |
Why?
|
| Community Health Workers | 1 | 2010 | 66 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 17 | 0.020 |
Why?
|
| Rural Population | 1 | 2013 | 654 | 0.020 |
Why?
|
| Peer Group | 1 | 2008 | 14 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2008 | 36 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 225 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 12 | 0.020 |
Why?
|
| Gentian Violet | 1 | 2007 | 1 | 0.020 |
Why?
|
| Phenazines | 1 | 2007 | 3 | 0.020 |
Why?
|
| Reference Standards | 1 | 2007 | 29 | 0.020 |
Why?
|
| Self Care | 1 | 2007 | 14 | 0.020 |
Why?
|
| Hospitals | 1 | 2006 | 103 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2005 | 4 | 0.020 |
Why?
|